TERSERA THERAPEUTICS LLC
BiotechTERSERA THERAPEUTICS LLC is a biotechnology company focused on Oncology.
FDA Novel Drug Designations
(2020)See 1 novel approval →
TERSERA THERAPEUTICS LLC's Key Drugs
TERSERA THERAPEUTICS LLC's core commercial portfolio centers on MARGENZA, spanning Oncology — its most strategically important drugs approved in the last 15 years.
TERSERA THERAPEUTICS LLC's Recent FDA Approvals
New NDA/BLA approvals for TERSERA THERAPEUTICS LLC over the last two years — novel drugs only, excluding generics and label supplements.
TERSERA THERAPEUTICS LLC's Therapeutic Areas
TERSERA THERAPEUTICS LLC's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
TERSERA THERAPEUTICS LLC's Top Competitors
TERSERA THERAPEUTICS LLC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
TERSERA THERAPEUTICS LLC Pipeline Snapshot
TERSERA THERAPEUTICS LLC has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MARGENZA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2020-12-16
- Latest
- 2025-01-15
- Applications
- 1